Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
| Last: | $2.295 |
|---|---|
| Change Percent: | -2.55% |
| Open: | $2.35 |
| Close: | $2.355 |
| High: | $2.445 |
| Low: | $2.29 |
| Volume: | 229,166 |
| Last Trade Date Time: | 03/06/2026 12:45:44 pm |
| Market Cap: | $604,677,102 |
|---|---|
| Float: | 98,372,842 |
| Insiders Ownership: | N/A |
| Institutions: | 82 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.prokidney.com |
| Country: | US |
| City: | Winston-Salem |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about ProKidney Corp. (NASDAQ: PROK).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
